[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA116794C2 - Моноциклічна піридинова похідна - Google Patents

Моноциклічна піридинова похідна

Info

Publication number
UA116794C2
UA116794C2 UAA201508149A UAA201508149A UA116794C2 UA 116794 C2 UA116794 C2 UA 116794C2 UA A201508149 A UAA201508149 A UA A201508149A UA A201508149 A UAA201508149 A UA A201508149A UA 116794 C2 UA116794 C2 UA 116794C2
Authority
UA
Ukraine
Prior art keywords
group
hydrogen atom
atom
alkyl group
nitrogenated
Prior art date
Application number
UAA201508149A
Other languages
English (en)
Inventor
Сетсуо Фунасака
Тошімі Окада
Кеіго Танака
Сатоші Нагао
Ісао Охаші
Йошінобу Ямане
Юсуке Накатані
Юкі Кароджі
Original Assignee
Ейсей Р Енд Д Менеджмент Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ейсей Р Енд Д Менеджмент Ко., Лтд. filed Critical Ейсей Р Енд Д Менеджмент Ко., Лтд.
Publication of UA116794C2 publication Critical patent/UA116794C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

В даному винаході розкривається сполука, представлена наступною формулою (IA), або її фармацевтично прийнятна сіль: EMBED ChemDraw.Document.6.0 , де n дорівнює 0-2; A являє собою ариленову групу або гетероариленову групу; G являє собою одинарний зв'язок, атом кисню або -CH2-; E являє собою неароматичний гетероцикл, що містить азот; R1 являє собою алкоксигрупу, алкоксіалкоксигрупу або подібне; R2 являє собою атом водню, атом галогену, гідроксильну групу, алкільну групу, гідроксіалкільну групу, неароматичну гетероциклічну групу, що містить азот, або подібне; R3 являє собою атом водню, алкільну групу, алкоксигрупу або подібне; та R4 являє собою C1-6алкільну групу за умови, що, якщо E являє собою азетидинове кільце, а R2 або R3 знаходиться на атомі азоту в азетидиновому кільці, то R2 або R3 не є атомом водню.
UAA201508149A 2013-02-20 2014-02-18 Моноциклічна піридинова похідна UA116794C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361766922P 2013-02-20 2013-02-20
PCT/JP2014/053819 WO2014129477A1 (ja) 2013-02-20 2014-02-18 単環ピリジン誘導体

Publications (1)

Publication Number Publication Date
UA116794C2 true UA116794C2 (uk) 2018-05-10

Family

ID=51351646

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201508149A UA116794C2 (uk) 2013-02-20 2014-02-18 Моноциклічна піридинова похідна

Country Status (35)

Country Link
US (1) US8933099B2 (uk)
EP (1) EP2960238B1 (uk)
JP (2) JP5600229B1 (uk)
KR (1) KR102050128B1 (uk)
CN (1) CN105073730B (uk)
AR (1) AR094812A1 (uk)
AU (1) AU2014219811B2 (uk)
BR (1) BR112015019790B1 (uk)
CA (1) CA2901585C (uk)
CL (1) CL2015002311A1 (uk)
CY (1) CY1119220T1 (uk)
DK (1) DK2960238T3 (uk)
ES (1) ES2628495T3 (uk)
HK (1) HK1215949A1 (uk)
HR (1) HRP20170873T1 (uk)
HU (1) HUE032931T2 (uk)
IL (1) IL240623B (uk)
JO (1) JO3261B1 (uk)
LT (1) LT2960238T (uk)
ME (1) ME02755B (uk)
MX (1) MX361870B (uk)
MY (1) MY178760A (uk)
NZ (1) NZ711101A (uk)
PE (1) PE20151509A1 (uk)
PH (1) PH12015501813A1 (uk)
PL (1) PL2960238T3 (uk)
PT (1) PT2960238T (uk)
RS (1) RS56064B1 (uk)
RU (1) RU2645352C2 (uk)
SG (1) SG11201506488WA (uk)
SI (1) SI2960238T1 (uk)
TW (4) TWI672140B (uk)
UA (1) UA116794C2 (uk)
WO (1) WO2014129477A1 (uk)
ZA (1) ZA201505941B (uk)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015304465B2 (en) 2014-08-18 2019-05-09 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
KR102537152B1 (ko) * 2015-03-25 2023-05-26 국립연구개발법인 고쿠리츠간켄큐센터 담관암에 대한 치료제
EP3391885B1 (en) * 2015-12-17 2021-03-17 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
RU2020108284A (ru) * 2017-10-12 2021-11-12 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Фармацевтическая композиция, содержащая селективный ингибитор тирозинкиназы fgfr
US11219619B2 (en) 2018-03-28 2022-01-11 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
MX2022012934A (es) * 2020-04-17 2022-11-08 Eisai R&D Man Co Ltd Agente terapeutico para cancer de mama.
CN115996722A (zh) 2020-07-31 2023-04-21 卫材R&D管理有限公司 乳腺癌治疗剂
TW202233185A (zh) 2020-10-28 2022-09-01 日商衛材R&D企管股份有限公司 腫瘤治療用醫藥組合物
CA3227445A1 (en) * 2021-08-31 2023-03-09 Eisai R&D Management Co., Ltd. Production method for synthetic intermediate of monocyclic pyridine derivative
TW202328099A (zh) 2021-08-31 2023-07-16 日商衛材R&D企管股份有限公司 單環吡啶衍生物之製造方法
AU2023236231A1 (en) * 2022-03-18 2024-09-05 Shanghai Institute Of Materia Medica , Chinese Academy Of Sciences Salt of substituted amino six-membered nitric heterocyclic compound, crystal form thereof, method for preparing same, and use thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
RU2264389C3 (ru) 2000-10-20 2018-06-01 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Азотсодержащие ароматические производные, их применение, лекарственное средство на их основе и способ лечения
WO2002081420A1 (fr) 2001-04-03 2002-10-17 Eisai Co., Ltd. Derive de cyclooctanone et derive de cyclodecanone et utilisation de ces derives
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
AU2003261807B9 (en) 2002-08-30 2007-02-15 Eisai R & D Management Co., Ltd. Azaarene derivatives
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
RU2350617C2 (ru) 2003-04-10 2009-03-27 Ф.Хоффманн-Ля Рош Аг Пиримидиновые соединения, обладающие свойствами селективного ингибирования активности кдр и фрфр
US20050256154A1 (en) 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
WO2006127926A2 (en) * 2005-05-23 2006-11-30 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
MEP3808A (xx) 2005-12-21 2010-02-10 Novartis Ag Derivati pirimidinil aril uree kao fgf inhibitori
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1891955A1 (en) 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
CA2672172C (en) 2006-12-22 2016-05-03 Astex Therapeutics Limited Bicyclic heterocyclic compounds as fgfr inhibitors
CA2690355A1 (en) 2007-06-25 2008-12-31 Qinetiq Limited Preconcentrator device incorporating a polymer of intrinsic microporosity
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
WO2009076660A2 (en) * 2007-12-13 2009-06-18 Tyratech, Inc. Organic absorbent material and uses thereof
CL2008003675A1 (es) * 2007-12-13 2009-03-20 Wyeth Corp Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide.
CN102036963B (zh) 2008-05-23 2013-08-21 诺瓦提斯公司 作为蛋白酪氨酸激酶抑制剂的喹啉类和喹喔啉类衍生物
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
WO2009153592A1 (en) 2008-06-19 2009-12-23 Astrazeneca Ab Pyrazole compounds 436
WO2010078430A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
US8263610B2 (en) 2008-12-30 2012-09-11 Arqule, Inc. Substituted imidazolyl-5,6-dihydrobenzo[N]isoquinoline compounds
DK2379506T3 (en) 2008-12-30 2015-12-14 Arqule Inc Substituted 5,6-dihydro-6-phenylbenzo [f] isoquinolin-2-amine compounds
US9002427B2 (en) 2009-03-30 2015-04-07 Lifewave Biomedical, Inc. Apparatus and method for continuous noninvasive measurement of respiratory function and events
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
FR2947546B1 (fr) 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
CN102574836B (zh) 2009-08-07 2014-04-16 中外制药株式会社 氨基吡唑衍生物
ES2524548T3 (es) 2009-10-30 2014-12-10 Novartis Ag N-óxido de 3-(2,6-dicloro-3,5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperacin-1-il)-fenilamino]-pirimidin-4-il}-1-metil-urea
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
US8754114B2 (en) 2010-12-22 2014-06-17 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
BR112014017749B1 (pt) 2012-01-19 2021-08-03 Taiho Pharmaceutical Co., Ltd. Composto alquinilbenzeno 3,5-dissubstituído e sal do mesmo
AR090161A1 (es) 2012-02-28 2014-10-22 Astellas Pharma Inc Derivados heterociclicos nitrogenados con accion sobre el cancer de vejiga
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
LT3495367T (lt) 2012-06-13 2021-02-25 Incyte Holdings Corporation Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
BR112015000653A2 (pt) 2012-07-11 2019-11-05 Blueprint Medicines Corp compostos inibidores do receptor de fator de crescimento de fibroblasto, sua composição farmacêutica e seus usos
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
RU2673943C2 (ru) 2012-09-27 2018-12-03 Чугаи Сейяку Кабусики Кайся Fgfr3 гибридный ген и лекарственный препарат, нацеленный на него
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑

Also Published As

Publication number Publication date
AR094812A1 (es) 2015-08-26
ES2628495T3 (es) 2017-08-03
TW201902889A (zh) 2019-01-16
AU2014219811B2 (en) 2017-09-28
JPWO2014129477A1 (ja) 2017-02-02
TW201900169A (zh) 2019-01-01
BR112015019790A2 (pt) 2017-07-18
TWI672139B (zh) 2019-09-21
CA2901585C (en) 2019-09-24
ZA201505941B (en) 2016-07-27
TWI672296B (zh) 2019-09-21
BR112015019790B1 (pt) 2020-12-01
HRP20170873T1 (hr) 2017-09-08
TWI672140B (zh) 2019-09-21
US20140235614A1 (en) 2014-08-21
JO3261B1 (ar) 2018-09-16
CY1119220T1 (el) 2018-02-14
PE20151509A1 (es) 2015-10-18
CN105073730B (zh) 2017-10-13
WO2014129477A1 (ja) 2014-08-28
EP2960238A4 (en) 2016-08-17
CN105073730A (zh) 2015-11-18
RS56064B1 (sr) 2017-10-31
PT2960238T (pt) 2017-06-05
NZ711101A (en) 2018-08-31
CL2015002311A1 (es) 2016-02-05
TW201900168A (zh) 2019-01-01
JP5600229B1 (ja) 2014-10-01
RU2015134558A (ru) 2017-03-24
MX2015010698A (es) 2016-04-11
IL240623A0 (en) 2015-10-29
EP2960238B1 (en) 2017-04-05
PL2960238T3 (pl) 2017-09-29
IL240623B (en) 2019-03-31
DK2960238T3 (en) 2017-06-26
US8933099B2 (en) 2015-01-13
EP2960238A1 (en) 2015-12-30
HUE032931T2 (en) 2017-11-28
SG11201506488WA (en) 2015-09-29
SI2960238T1 (sl) 2017-07-31
CA2901585A1 (en) 2014-08-28
LT2960238T (lt) 2017-07-10
TWI641602B (zh) 2018-11-21
MY178760A (en) 2020-10-20
PH12015501813A1 (en) 2015-12-07
KR20150118151A (ko) 2015-10-21
AU2014219811A1 (en) 2015-09-03
RU2645352C2 (ru) 2018-02-21
ME02755B (me) 2018-01-20
TW201439085A (zh) 2014-10-16
MX361870B (es) 2018-12-18
HK1215949A1 (zh) 2016-09-30
JP2014237707A (ja) 2014-12-18
KR102050128B1 (ko) 2019-11-28

Similar Documents

Publication Publication Date Title
UA116794C2 (uk) Моноциклічна піридинова похідна
PH12015502232A1 (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
IN2014MN01897A (uk)
SA515361086B1 (ar) Fasn مركبات وتركيبات جديدة لتثبيط
CA2875877C (en) Syk inhibitors
PH12014501719A1 (en) Pyridone derivatives
TN2015000175A1 (en) Heteroaryl substituted pyridyl compounds useful as kinase modulators
PH12016501079A1 (en) (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]-4,7-DIOXO-8-({6-[3-(PIPERAZINE-1-YL)AZETIDINE-1-YL]PYRIDINE-2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND
MX2009004920A (es) Nuevos derivados de aminopirimidina como inhibidores de plk1.
MX360858B (es) Compuesto heterocíclico que contiene nitrógeno parcialmente saturado.
MX2017005158A (es) Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk).
PH12019501391A1 (en) Novel compound and pharmacologically acceptable salt thereof
PH12016500152A1 (en) Novel triazine derivative
PH12015501146A1 (en) Hydantoin derivative
MX2016006004A (es) Derivado de carboximetil piperidina.
MY176508A (en) Anti-enterovirus 71 thiadiazolidine derivative
MX355654B (es) Derivado de paroxetina.
PH12015501056A1 (en) 2-pyridone compound
MX358151B (es) Derivado de sitaxentan.
MX362994B (es) Preparacion farmaceutica que comprende un derivado de aminopirazol.
BR112016005897A2 (pt) derivado de triazina
GB201013509D0 (en) Compounds